Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]
Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.
Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome
1.
Ineffective medication can remove the "worst fear" of schizophrenia.
2.
Herpes virus-based vaccine shows promise in targeting tumors without side effects
3.
The pandemic had little impact on mental health symptoms.
4.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
5.
Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.
1.
Exploring the Potential of Xospata: A New Frontier in Cancer Treatment
2.
Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization
3.
ERASur: Evaluating Total Ablative Therapy in Limited Metastatic Colorectal Cancer
4.
Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology
5.
Carboplatin Treatment: What You Need to Know About Side Effects and Efficacy
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Navigating the Complexities of Ph Negative ALL - Part XV
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge